如何利用基因魔剪—CRISPR技术来进行非编码基因组功能的研究?

2016-10-23 佚名 生物谷

我们或许才刚刚开始打开对巨大的基因组非编码区域的研究,基于CRISPR的两项新技术或许就能够帮我们开启研究的新篇章。我们(原文笔者)能够很好地理解基因组中编码蛋白组分背后的规则,同时通过对DNA序列的观察我们也能够找出从事编码作用的基因的开始以及终止位置。 对于基因组中残留的98%的基因组而言,却又是一番不同的故事了,如今我们对于DNA暗物质的理解都是来自于对非编码DNA单个

我们或许才刚刚开始打开对巨大的基因组非编码区域的研究,基于CRISPR的两项新技术或许就能够帮我们开启研究的新篇章。我们(原文笔者)能够很好地理解基因组中编码蛋白组分背后的规则,同时通过对DNA序列的观察我们也能够找出从事编码作用的基因的开始以及终止位置。

对于基因组中残留的98%的基因组而言,却又是一番不同的故事了,如今我们对于DNA暗物质的理解都是来自于对非编码DNA单个片段的研究和理解,而真正指导非编码基因组发挥作用的规则目前研究者并不清楚。博德研究所的创始主任Eric Lander说道,90%的影响人类疾病的遗传突变都位于非编码区域,但如今我们并没有有效的方法去阐明到底是哪些调节子在影响着这些基因的表达

刊登在Science杂志上的一篇研究报告中,来自博德研究所的两个研究团队通过研究利用CRISPR基因编辑技术揭示了非编码基因工作的机制。利用两种互补的方法,研究人员以CRISPR作为工具系统性地同时调查了数千个非编码的DNA序列,研究人员(来自Lander实验室和来自Zhang Feng实验室的研究者)在研究中鉴别出了多个非常有意思的遗传调节子,其中就包括那些远离所控制基因位点的数以百万计的碱基。

研究者Jesse Engreitz指出,我们希望能够在每个细胞周期中对控制每个基因表达的非编码元件进行编录,这在生物学研究上是一个非常大的问题,而且这也是一个限速的步骤,即将和基础分子机制相关的许多遗传特性同人类疾病相联系。

变化多端

目前两个研究小组都利用了CRISPR进行了相关筛查来干扰非编码的DNA,但两个研究小组却是利用不同的方法来进行了相关研究。研究者张峰(Zhang Feng)利用Cas9来对非编码DNA的重叠延伸片段进行精准的切割,在这种情况下,围绕在三个基因NF1, NF2和CUL3周围区域的功能就会丧失,而这与某些形式的黑色素瘤耐药性产生直接相关。研究者解释道,这种方法就能够帮助我们诱导一系列多样性突变的产生,而且我们也不必推测既定的序列为何会被干扰。

另外一组研究者Engreitz等人则利用了CRISPR的干扰系统,即利用失活形式的Cas9同KRAB蛋白相互融合从而沉默靶向序列的表达,这些靶向序列围绕在MYC和GATA1附近,这两个基因是重要的转录因子。Engreitz说道,这种系统能够帮助我们队非编码区域的调节性影响进行定量的评估,同时其还能够为我们展示如何能够控制一个既定的基因。

每个研究小组都利用了一种功能性的“读数器”以及深度的测序技术观察了哪种导向RNAs能够影响目标基因的表达,同时还能够帮助绘制出导向RNAs所影响的调节子的图谱。两个研究团队的研究结果都阐明了利用CRISPR工具追踪非编码基因组调节机制的重要性。研究者Engreitz等人阐明了7个MYC和3个GATA1增强子的重要性,而张峰研究团队则筛选出了多个增强子以及仅结合CUL3的转录因子结合位点。

在“自然栖息地”对序列进行研究

类似于传统的报道分子实验,即科学家们感兴趣的在质粒中将序列同报道自偶联进行研究;这些混合的CRISPR筛选技术有着明显的不同,其能够直接探查序列,也就是说在最原始的位点进行序列的研究解读。研究者Sanjana强调道,这些筛选技术能够从内源性的角度来对序列进行研究,同时报道子实验也是非常有帮助的,但其缺少了3D构象和局部的染色质环境,在这里这些调节性序列或许就会经历正常的一些相互作用。

研究者表示,举个例子说,我们或许能够在基因启动子和非编码位点之间观察到长期的循环结构,但如果我们仅仅观察这些调节性原件的话或许就会错过一些感兴趣的3D相互作用。Engreitz指出,目前存在一种限制,不管是CRISPR方法还是别的方法,在当前的形式下,发现基因组固有的冗余程度或许并不足以破碎一种增强子来理解基因被控制机制,或许我们需要对多个增强子进行打断来研究。

但Engreitz及其同事表示非常乐观,他们希望能够利用基于CRISPR的技术来阐明非编码基因组背后所隐藏的秘密。目前在非编码基因组上研究的最大挑战就是,尽管非编码基因组非常庞大,但其中所包含的单一功能性元件却是非常小的,未来研究者希望开发新的研究方法在保证非编码基因组较高分辨率的情况下对更大的基因组区域进行探索。

研究者指出,随着他们绘制出多个图谱以及其相关性,他们相信能够帮助预测关于非编码基因组的一些信息;利用导向RNAs文库引入CRISPR或者抑制子或许就能够帮助研究者阐明大块区域的非编码DNA对不同基因的作用以及效应,而届时科学家们或许才刚刚打开对基因调节的系统性图谱研究的第一步。

参考资料:

【1】Reading the rules of gene regulation with CRISPR

【2】High-resolution interrogation of functional elements in the noncoding genome

Science   DOI: 10.1126/science.aaf7613

【3】Systematic mapping of functional enhancer-promoter connections with CRISPR interference

Science    DOI: 10.1126/science.aag2445

【4】A massive approach to finding what's "real" in genome-wide association data

【5】CRISPR system scales up in human cells

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1743432, encodeId=22b81e4343249, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Jan 13 20:49:00 CST 2017, time=2017-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805912, encodeId=1bc0180591210, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Thu Jan 05 03:49:00 CST 2017, time=2017-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683427, encodeId=eb01168342e36, content=<a href='/topic/show?id=a576102854fe' target=_blank style='color:#2F92EE;'>#魔剪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102854, encryptionId=a576102854fe, topicName=魔剪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c09b27973273, createdName=neurosurgeon, createdTime=Sat Apr 01 17:49:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275932, encodeId=46ce12e5932d0, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584649, encodeId=811a158464954, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618695, encodeId=9c0516186954d, content=<a href='/topic/show?id=e798524076' target=_blank style='color:#2F92EE;'>#Crispr技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5240, encryptionId=e798524076, topicName=Crispr技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a49419938232, createdName=ms1779634646866130, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
    2017-01-13 d830384
  2. [GetPortalCommentsPageByObjectIdResponse(id=1743432, encodeId=22b81e4343249, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Jan 13 20:49:00 CST 2017, time=2017-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805912, encodeId=1bc0180591210, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Thu Jan 05 03:49:00 CST 2017, time=2017-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683427, encodeId=eb01168342e36, content=<a href='/topic/show?id=a576102854fe' target=_blank style='color:#2F92EE;'>#魔剪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102854, encryptionId=a576102854fe, topicName=魔剪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c09b27973273, createdName=neurosurgeon, createdTime=Sat Apr 01 17:49:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275932, encodeId=46ce12e5932d0, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584649, encodeId=811a158464954, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618695, encodeId=9c0516186954d, content=<a href='/topic/show?id=e798524076' target=_blank style='color:#2F92EE;'>#Crispr技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5240, encryptionId=e798524076, topicName=Crispr技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a49419938232, createdName=ms1779634646866130, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1743432, encodeId=22b81e4343249, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Jan 13 20:49:00 CST 2017, time=2017-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805912, encodeId=1bc0180591210, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Thu Jan 05 03:49:00 CST 2017, time=2017-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683427, encodeId=eb01168342e36, content=<a href='/topic/show?id=a576102854fe' target=_blank style='color:#2F92EE;'>#魔剪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102854, encryptionId=a576102854fe, topicName=魔剪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c09b27973273, createdName=neurosurgeon, createdTime=Sat Apr 01 17:49:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275932, encodeId=46ce12e5932d0, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584649, encodeId=811a158464954, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618695, encodeId=9c0516186954d, content=<a href='/topic/show?id=e798524076' target=_blank style='color:#2F92EE;'>#Crispr技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5240, encryptionId=e798524076, topicName=Crispr技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a49419938232, createdName=ms1779634646866130, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1743432, encodeId=22b81e4343249, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Jan 13 20:49:00 CST 2017, time=2017-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805912, encodeId=1bc0180591210, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Thu Jan 05 03:49:00 CST 2017, time=2017-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683427, encodeId=eb01168342e36, content=<a href='/topic/show?id=a576102854fe' target=_blank style='color:#2F92EE;'>#魔剪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102854, encryptionId=a576102854fe, topicName=魔剪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c09b27973273, createdName=neurosurgeon, createdTime=Sat Apr 01 17:49:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275932, encodeId=46ce12e5932d0, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584649, encodeId=811a158464954, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618695, encodeId=9c0516186954d, content=<a href='/topic/show?id=e798524076' target=_blank style='color:#2F92EE;'>#Crispr技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5240, encryptionId=e798524076, topicName=Crispr技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a49419938232, createdName=ms1779634646866130, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
    2016-10-25 yuandd
  5. [GetPortalCommentsPageByObjectIdResponse(id=1743432, encodeId=22b81e4343249, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Jan 13 20:49:00 CST 2017, time=2017-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805912, encodeId=1bc0180591210, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Thu Jan 05 03:49:00 CST 2017, time=2017-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683427, encodeId=eb01168342e36, content=<a href='/topic/show?id=a576102854fe' target=_blank style='color:#2F92EE;'>#魔剪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102854, encryptionId=a576102854fe, topicName=魔剪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c09b27973273, createdName=neurosurgeon, createdTime=Sat Apr 01 17:49:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275932, encodeId=46ce12e5932d0, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584649, encodeId=811a158464954, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618695, encodeId=9c0516186954d, content=<a href='/topic/show?id=e798524076' target=_blank style='color:#2F92EE;'>#Crispr技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5240, encryptionId=e798524076, topicName=Crispr技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a49419938232, createdName=ms1779634646866130, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1743432, encodeId=22b81e4343249, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Jan 13 20:49:00 CST 2017, time=2017-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805912, encodeId=1bc0180591210, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Thu Jan 05 03:49:00 CST 2017, time=2017-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683427, encodeId=eb01168342e36, content=<a href='/topic/show?id=a576102854fe' target=_blank style='color:#2F92EE;'>#魔剪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102854, encryptionId=a576102854fe, topicName=魔剪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c09b27973273, createdName=neurosurgeon, createdTime=Sat Apr 01 17:49:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275932, encodeId=46ce12e5932d0, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584649, encodeId=811a158464954, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618695, encodeId=9c0516186954d, content=<a href='/topic/show?id=e798524076' target=_blank style='color:#2F92EE;'>#Crispr技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5240, encryptionId=e798524076, topicName=Crispr技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a49419938232, createdName=ms1779634646866130, createdTime=Tue Oct 25 10:49:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]

相关资讯

Nature:CRISPR技术背后的无名英雄们

CRISPR技术大热,成就了一大波学术明星。但这些学术大牛们的研究生和博后们的贡献往往会被忽略。 当Blake Wiedenheft开始学习微生物时,他的工作颇有些不切实际,前途不明。 他的博士生涯主要是对国家黄石公园的温泉进行取样,然后人工仿造温泉中的微生物。 Wiedenheft指出,他们想知道,这些微生物是如何在高温、强酸的环境中生存的。 随着时间的推移,Wiedenheft对微生

盘点:2015年基因编辑领域重磅级研究TOP10

2015年12月1-3日,在华盛顿特区召开了一次大型国际会议,人类基因组编辑的伦理学将会再次成为召开的一个的主题。这次峰会将由美国国家科学院、美国国家医学科学院、中国科学院和英国皇家学会联合组织,这次会议中各国研究人员还将对人类的基因组编辑的众多问题进行讨论;那么在即将过去的2015年里,基因编辑领域有哪些亮点研究呢?请看2015年基因编辑领域研究TOP10。

CRISPR不是张锋的?基因编辑工具的专利之争

从2012年开始,CRISPR/Cas9被用于很多生物系统中进行基因组编辑,在各大顶级期刊上发表了大量文章,可算是赚足了眼球。随着CRISPR/Cas9基因编辑系统逐渐进化,并趋于成熟,从学术界的共享走向专利申请以及商业化的道路也逐渐清晰起来。然而面前还存在着很多问题,例如,CRISPR/Cas9的专利申请之路就并不那么顺利。 CRISPR/Cas9是什么? CRISPR/Cas9,是

Science:CRISPR先驱发表新成果!

来自加州大学伯克利分校、德国马克斯普朗克生物物理化学研究所的研究人员揭示出了为识别靶DNA,预先组织形成的一种Cas9-导向RNA(gRNA)复合物的构象。这项研究发布在近期的《科学》(Science)杂志上。文章的通讯作者是加州大学伯克利分校的Jennifer A. Doudna博士。Doudna是CRISPR技术的共同开发者,曾因这一技术获得了“生命科学突破奖”(Breakthrough Pr

科学家有望使用Crispr技术治疗肝病

根据英国《每日邮报》报道,科学家首次利用基因组编辑技术治愈成年老鼠活体所患的遗传性肝脏疾病。由此我们可以看到此项技术的应用前景,该技术用于治疗人类肝病的时代将指日可待了。 这项名为Crispr的技术可对庞大的脱氧核糖核酸(DNA)数据库作出科学家所称的高精度微调。 科学家使用Crispr技术修正了老鼠遗传字母表中的一个“字母”,这个发生突变的“字母”位于一个与肝脏代谢有关的基因中。 新技

MIT:CRISPR技术再升级,走入精准控制时代

如果说到近几年来生物学领域取得的重大突破,或许很多人都会提到CRISPR。作为一项极具潜力的基因编辑技术,CRISPR不但在新药研发的高通量筛选过程中扮演了越来越重要的角色,更有直接应用于临床的能力——今年6月,美国NIH下属的重组DNA咨询委员会投票一致通过CRISPR可用于人体基因编辑。而在7月,四川大学华西医院的科学家也宣布将把CRISPR技术应用于人体,以期治疗非小细胞肺癌。不难想象,未来